CPO_Aβ17-21P
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD.
For research use only. We do not sell to patients.
- Formula: C37H49N7O7
- Molecular Weight:703.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
CPO_Aβ17-21P (2 μM; 7-10 d) potently inhibits apoE4-mediated fibrillization of Aβ40 and Aβ42[1].
CPO_Aβ17-21P (1-4 μM; 3 d) dose-dependently inhibits apoE4-enhanced Aβ42 cytotoxicity in human SK-N-SH neuroblastoma cells, and exerts significant rescue effects at concentrations of 1 μM and 4 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human SK-N-SH neuroblastoma cells
-
Concentration:1 μM, 4 μM
-
Incubation Time:6 hrs (pre-incubation with apoE4 at 37 °C); 3 days (incubation with cells)
-
Result:Significantly neutralized apoE4-potentiated Aβ42 cytotoxicity at 1 μM.
Significantly neutralized apoE4-potentiated Aβ42 cytotoxicity at 4 μM.
Showed a greater rescue effect at the higher 4 μM concentration.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:APP/PS1 transgenic mice (5 male, 6 female per group; 3 months old; Alzheimer's disease model)[1]
-
Dosage:0.2 mg per mouse
-
Administration:i.p.; twice weekly; 4 months
-
Result:Improved spatial working memory.
Reduced total amyloid burden in the cortex and hippocampus compared to vehicle controls.
Reduced soluble Aβ40, insoluble Aβ40, and Aβ42 levels in brain tissue.
Reduced brain oligomeric Aβ levels.
Reduced hippocampal astrogliosis and cortical microgliosis.
Showed no significant difference in plasma total cholesterol levels compared to vehicle controls.
Showed no significant differences in locomotor activity, rotarod performance, or traverse beam performance compared to vehicle controls.
Chemical Information
-
Molecular Weight 703.83
-
Formula C37H49N7O7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CPO_Aβ17-21P Related Classifications
HY-P11677 Related Classifications
Powered by Bioz